<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803851</url>
  </required_header>
  <id_info>
    <org_study_id>JS2791</org_study_id>
    <nct_id>NCT04803851</nct_id>
  </id_info>
  <brief_title>Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer</brief_title>
  <official_title>Anlotinib Plus Anti-PD-1 Antibody AK105 as Third or More-line Therapy for Advanced Pancreatic Cancer: a Prospective, Single-arm, Open-label, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1&#xD;
      antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer&#xD;
      patients, in order to find a better therapy strategy for pancreatic cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">February 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR) based on RECIST v. 1 1</measure>
    <time_frame>6 weeks</time_frame>
    <description>Disease control rate (DCR) based on RECIST v. 1 1 by investigators</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on RECIST V. 1.1</measure>
    <time_frame>6 weeks</time_frame>
    <description>Objective response rate (ORR) based on RECIST V. 1.1 by investigators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) measured from the date of anlotinib plus AK105 initiation to the time of progression</measure>
    <time_frame>6 weeks</time_frame>
    <description>Progression free survival (PFS) measured from the date of anlotinib plus AK105 initiation to the time of progression by investigators assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) measured from the date of anlotinib plus AK105 initiation to the time of death of any cause</measure>
    <time_frame>6 weeks</time_frame>
    <description>Overall survival (OS) measured from the date of anlotinib plus AK105 initiation to the time of death of any cause by investigators assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 weeks</time_frame>
    <description>adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Anlotinib</condition>
  <condition>Anti-PD-1 Antibody</condition>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib plus AK105</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib plus AK105</intervention_name>
    <description>Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  locally advanced or metastatic pancreatic cancer (PC),&#xD;
&#xD;
          -  histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous&#xD;
             carcinoma,&#xD;
&#xD;
          -  failed to second-line chemotherapy for PC,&#xD;
&#xD;
          -  18-75 years of age,&#xD;
&#xD;
          -  an Eastern Cooperative Oncology Group performance status score of 0 to 1,&#xD;
&#xD;
          -  adequate organ functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  had received PD 1 /CTLA 4 antibody treatment&#xD;
&#xD;
          -  had received anti-VEGFR inhibitors or antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>XIANG WANG, Master</last_name>
    <phone>86-1069158773</phone>
    <email>wangxiang5123@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiang Wang, Doctor</last_name>
      <phone>011-86-10-69151279</phone>
      <email>wangxiang5123@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

